Dr Reddy’s Stock Drops on Regulatory Setback for Weight-Loss Drug

Dr. Reddy’s Laboratories shares fell nearly 6% today following a non-compliance notice from Canadian regulators that delayed the launch of its weight-loss drug Semaglutide in Canada by six months. This delay could cost the company millions in potential revenue over the next two years. Despite reporting a 7% rise in Q2 net profit recently, the regulatory setback dented investor sentiment, pushing the stock lower. 🔹 As of 30 Oct 2025,

hit its lowest level in four months but managed to reject a support-level breakdown, closing above immediate support — signaling resilience at key technical levels. The pharma major now faces the challenge of regaining investor confidence while addressing regulatory concerns in international markets. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.